1Sajatovic, M, Strejilevich, SA, Gildengers, AG, Dols, A, Al Jurdi, RK, Forester, BP, et al. A report on older-age bipolar disorder from the International Society for Bipolar Disorders Task Force. Bipolar Disord 2015; 17: 689–704.
2Crump, C, Sundquist, K, Winkleby, MA, Sundquist, J. Comorbidities and mortality in bipolar disorder: a Swedish national cohort study. JAMA Psychiatry 2013; 70: 931–9.
3Tsai, SY, Lee, CH, Kuo, CJ, Chen, CC. A retrospective analysis of risk and protective factors for natural death in bipolar disorder. J Clin Psychiatry 2005; 66: 1586–91.
4Correll, CU, Detraux, J, De Lepeleire, J, De Hert, M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry 2015; 14: 119–36.
5Lan, CC, Liu, CC, Lin, CH, Lan, TY, McInnis, MG, Chan, CH, et al. A reduced risk of stroke with lithium exposure in bipolar disorder: a population-based retrospective cohort study. Bipolar Disord 2015; 17: 705–14.
6Prosser, JM, Fieve, RR. Patients receiving lithium therapy have a reduced prevalence of neurological and cardiovascular disorders. Prog Neuropsychopharmacol Biol Psychiatry 2016; 71: 39–44.
7Olesen, JB, Abildstrom, SZ, Erdal, J, Gislason, GH, Weeke, P, Andersson, C, et al. Effects of epilepsy and selected antiepileptic drugs on risk of myocardial infarction, stroke, and death in patients with or without previous stroke: a nationwide cohort study. Pharmacoepidemiol Drug Saf 2011; 20: 964–71.
8Chuang, YC, Chuang, HY, Lin, TK, Chang, CC, Lu, CH, Chang, WN, et al. Effects of long-term antiepileptic drug monotherapy on vascular risk factors and atherosclerosis. Epilepsia 2012; 53: 120–8.
9WHO. Manual of the International Statistical Classification of Diseases, Injuries and Causes of Death (9th revision) (ICD-9). World Health Organization, 1977.
10Wu, CS, Wang, SC, Gau, SS, Tsai, HJ, Cheng, YC. Association of stroke with the receptor-binding profiles of antipsychotics-a case-crossover study. Biol Psychiatry 2013; 73: 414–21.
11WHO Collaborating Centre for Drug Statistic Methodology. ATC Index with DDDs. World Health Organization, 2009.
12Charlson, ME, Pompei, P, Ales, KL, MacKenzie, CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373–83.
13Chen, WY, Chen, LY, Liu, HC, Wu, CS, Yang, SY, Pan, CH, et al. Antipsychotic medications and stroke in schizophrenia: a case-crossover study. PLoS One 2017; 12: e0179424.
14Hu, HH, Sheng, WY, Chu, FL, Lan, CF, Chiang, BN. Incidence of stroke in Taiwan. Stroke 1992; 23: 1237–41.
15Lopinto-Khoury, C, Mintzer, S. Antiepileptic drugs and markers of vascular risk. Curr Treat Options Neurol 2010; 12: 300–8.
16Lorenz, MW, Polak, JF, Kavousi, M, Mathiesen, EB, Volzke, H, Tuomainen, TP, et al. Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data. Lancet 2012; 379: 2053–62.
17Miao, Y, Liao, JK. Potential serum biomarkers in the pathophysiological processes of stroke. Expert Rev Neurother 2014; 14: 173–85.
18Chen, HF, Xu, LP, Luo, ZY, Yu, ZQ, Li, ZY, Cui, QY, et al. Valproic acid-associated low fibrinogen and delayed intracranial hemorrhage: case report and mini literature review. Drug Des Devel Ther 2013; 7: 767–70.
19Nanau, RM, Neuman, MG. Adverse drug reactions induced by valproic acid. Clin Biochem 2013; 46: 1323–38.
20Choi, SE, Jang, HJ, Kang, Y, Jung, JG, Han, SJ, Kim, HJ, et al. Atherosclerosis induced by a high-fat diet is alleviated by lithium chloride via reduction of VCAM expression in ApoE-deficient mice. Vascul Pharmacol 2010; 53: 264–72.
21Wang, Z, Zhang, X, Chen, S, Wang, D, Wu, J, Liang, T, et al. Lithium chloride inhibits vascular smooth muscle cell proliferation and migration and alleviates injury-induced neointimal hyperplasia via induction of PGC-1alpha. PLoS One 2013; 8: e55471.
22Sacchetti, E, Trifiro, G, Caputi, A, Turrina, C, Spina, E, Cricelli, C, et al. Risk of stroke with typical and atypical anti-psychotics: a retrospective cohort study including unexposed subjects. J Psychopharmacol 2008; 22: 39–46.
23Zornberg, GL, Jick, H. Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study. Lancet 2000; 356: 1219–23.
24Janicak, PG. The relevance of clinical pharmacokinetics and therapeutic drug monitoring: anticonvulsant mood stabilizers and antipsychotics. J Clin Psychiatry 1993; 54(Suppl): 35–41; discussion 55–6.
25Fiedorowicz, JG, Solomon, DA, Endicott, J, Leon, AC, Li, C, Rice, JP, et al. Manic/hypomanic symptom burden and cardiovascular mortality in bipolar disorder. Psychosom Med 2009; 71: 598–606.
26Chen, PH, Chang, CK, Chiang, SJ, Lin, YK, Tsai, SY, Huang, SH. Diabetes mellitus and first episode mania associated with cardiovascular diseases in patients with older-age bipolar disorder. Psychiatry Res 2017; 249: 65–9.
27Ward, MC, White, DT, Druss, BG. A meta-review of lifestyle interventions for cardiovascular risk factors in the general medical population: lessons for individuals with serious mental illness. J Clin Psychiatry 2015; 76: e477–86.